Literature DB >> 4033630

High affinity binding of [3H]acetylcholine to muscarinic receptors. Regional distribution and modulation by guanine nucleotides.

D Gurwitz, Y Kloog, M Sokolovsky.   

Abstract

The interaction of [3H]acetylcholine ([3H]AcCh) with the muscarinic receptor was studied in seven distinct rat brain regions and in heart atrium by employing 10 microM atropine to define specific binding. The specific binding exhibited by the labeled neurotransmitter was found to be sensitive to muscarinic but not to nicotinic drugs. The muscarinic high affinity agonist-binding sites were characterized with respect to their binding properties, regional distribution, pharmacology, and modulation by guanyl nucleotides and by transition metal ions. In all tissues examined, specific binding of [3H]AcCh was saturable over the range of 4-200 nM and occurred in a receptor population that was apparently homogeneous and had a dissociation constant of approximately 19-39 nM in most of the regions. The ratio of muscarinic receptors labeled by [3H]AcCh to those labeled by the potent antagonist [3H]N-methyl-4-piperidylbenzilate varied markedly among tissues, from 0.15 in the hippocampus to 0.71 in the atrium. This ratio was lower in brain regions rich in muscarinic receptors, where smaller sensitivity of [3H]AcCh binding to guanyl nucleotides was also observed. In the presence of the latter [3H]AcCh binding was decreased by 25 to 90% in different tissues, with the greatest decreases occurring in the atrium and brainstem. In the latter preparations, transition metal ions do not affect [3H] AcCh binding, while in the other preparations studied they induce an increase in the binding capacity for the labeled neurotransmitter, which is sensitive to guanine nucleotides.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033630

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Modulation of agonist binding by guanine nucleotides in CHO cells expressing muscarinic m1-m5 receptors.

Authors:  P L van Giersbergen; R Leppik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

2.  Binding studies with [3H]cis-methyldioxolane in different tissues. Under certain conditions [3H]cis-methyldioxolane labels preferentially but not exclusively agonist high affinity states of muscarinic M2 receptors.

Authors:  A Closse; H Bittiger; D Langenegger; A Wanner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

3.  An [3H]oxotremorine binding method reveals regulatory changes by guanine nucleotides in cholinergic muscarinic receptors of cerebral cortex.

Authors:  S Raskovsky; J S Aguilar; D Jerusalinsky; E De Robertis
Journal:  Neurochem Res       Date:  1988-06       Impact factor: 3.996

4.  Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover.

Authors:  R Stein; R Pinkas-Kramarski; M Sokolovsky
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

5.  Methyllycaconitine- and scopolamine-induced cognitive dysfunction: differential reversal effect by cognition-enhancing drugs.

Authors:  Emile Andriambeloson; Bertrand Huyard; Etienne Poiraud; Stéphanie Wagner
Journal:  Pharmacol Res Perspect       Date:  2014-06-09

6.  Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.

Authors:  Jan Jakubík; Alena Randáková; Esam E El-Fakahany; Vladimír Dolezal
Journal:  BMC Pharmacol       Date:  2009-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.